3b blackbio dx Limited has released the transcript of its Q3 FY26 earnings conference call held on February 21, 2026, providing comprehensive insights into the company's financial performance and strategic initiatives following its successful participation at MEDLAB Dubai.

Strong Financial Performance with Coris Integration

The company reported robust nine-month revenue growth, with consolidated figures reaching INR99.06 crores compared to INR64.80 crores in the previous year. The standalone 3B business demonstrated solid growth of 11.8%, which would have been over 20% excluding seasonal fluctuations from dengue and flu outbreaks.

Coris Acquisition Performance and HAT Contract

The Belgium-based Coris acquisition contributed INR24 crores in quarterly revenue, including INR8.8 crores from the one-off HAT (Human African Trypanosomiasis) contract. This contract, originally valued at USD6 million over four years, is expected to continue generating approximately USD1.5 million annually for the next two years.

Market Position and Competitive Landscape

Chairman and Managing Director Dhirendra Dubey highlighted the company's strong market position, commanding 12-15% market share in India's molecular diagnostics reagent market, valued at approximately INR400-500 crores. The company exports to 70 countries, with TRUPCR Europe showing 20%+ growth driven by "Made in UK" credibility.

Strategic Initiatives and Product Development

The company is advancing several strategic initiatives including sample-to-answer machine development through OEM partnerships, automated extraction systems, and highly multiplexed panels for respiratory and AMR testing. The European IVDR certification process is underway for 35-40 key products, representing over 95% of European revenue.

Growth Outlook and Financial Guidance

Management provided guidance for 10-15% overall growth and 15-20% export growth for the current year. The company maintains a cash position of approximately INR190 crores post-Coris acquisition, with INR130-140 crores earmarked for future acquisitions. Two consultants have been appointed to identify acquisition opportunities.

Regulatory and Market Expansion

Coris has initiated US FDA registration processes, expected to complete within 1-2 years, opening access to the substantial US market. The company plans to participate in ADLM USA, showcasing products from all three entities: 3B, TRUPCR Europe, and Coris, targeting Latin American and US distributors.

3B BlackBio Dx Limited (formerly Kilpest India Limited) announced its unaudited financial results for the quarter and nine months ended December 31, 2025, showcasing robust performance across both standalone and consolidated operations. The Board of Directors approved these results at their meeting held on February 6, 2026.

Consolidated Financial Performance

The company delivered impressive consolidated results for Q3FY26, with significant growth across key financial metrics. The diagnostic kits segment emerged as a major growth driver, contributing substantially to the overall performance.

Nine-Month Performance Overview

For the nine months ended December 31, 2025, the consolidated performance showed consistent growth momentum across all major parameters.

Standalone Financial Results

The standalone operations also demonstrated solid performance, with revenue from operations reaching ₹2437.62 lakhs in Q3FY26 compared to ₹2343.00 lakhs in the corresponding previous quarter. Net profit for the standalone entity stood at ₹1446.02 lakhs versus ₹1344.84 lakhs in Q3FY25.

Segment-wise Performance

The company operates through two identified reportable business segments: Agrochemicals and Molecular Diagnostic Kits (Health Care Sector). The diagnostic kits segment showed remarkable performance with revenue of ₹4867.50 lakhs in Q3FY26 compared to ₹2328.30 lakhs in Q3FY25. The agrochemicals segment generated revenue of ₹167.23 lakhs during the quarter.

CORIS Acquisition Impact

The consolidated financials for Q3FY26 include CORIS sales of ₹2400.70 lakhs and profit of ₹700.10 lakhs. For the nine-month period, CORIS contributed sales of ₹2765.74 lakhs and profit of ₹658.20 lakhs, significantly enhancing the company's diagnostic capabilities and market presence.

Key Financial Highlights

Expense Management:

• Cost of materials consumed: ₹1367.34 lakhs (consolidated) vs ₹615.98 lakhs in Q3FY25
• Employee benefits expense: ₹821.31 lakhs vs ₹170.98 lakhs in previous year
• Other expenses included CE IVDR regulatory expenses and conference expenses

Balance Sheet Strength:

• Paid-up equity share capital: ₹856.84 lakhs
• Total segment assets: ₹41261.25 lakhs
• Capital employed: ₹35831.57 lakhs

Business Notes and Outlook

The company's agrochemical business remains seasonal in nature, with performance impacted by weather conditions and cropping patterns. The management noted that other expenses for the nine months included M&A expenses of ₹138.60 lakhs (₹84.06 lakhs in Q1 and ₹54.54 lakhs in Q2).

The company has evaluated the impact of new labour codes that became effective from November 21, 2025, determining that the impact on standalone financial results is not material. The results have been prepared in accordance with Indian Accounting Standards (Ind AS) and reviewed by Baheti & Co., Chartered Accountants.